ACBI3 molecule offers new hope for targeting KRAS mutations in cancer

KRAS is the most mutated gene in cancer with mutations occurring in 17%–25% of all cancers, affecting millions of patients worldwide.

J&J’s Megadyne discontinues pediatric electrode pad after burn reports

Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Johnson & Johnson’s Megadyne business

May 13, 2024

J&J shines spotlight on cancer specialty profession in new awareness and support effort

Multiple myeloma is a rare and complex blood cancer and often includes advanced practice providers, or APPs, as part of the patient care team. But

September 27, 2023

The association between viral infections and glioma risk

The causal relationship between viral infection and glioma.

December 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.